サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1541059

片頭痛治療薬市場レポート：治療タイプ、薬剤タイプ、投与経路、流通チャネル、地域別、2024～2032年

Migraine Drugs Market Report by Treatment Type, Drug Type, Route of Administration, Distribution Channel, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 146 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
片頭痛治療薬市場レポート：治療タイプ、薬剤タイプ、投与経路、流通チャネル、地域別、2024～2032年
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 146 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の片頭痛治療市場規模は2023年に42億米ドルに達しました。今後、IMARC Groupは、2024～2032年にかけて4.3%の成長率（CAGR）を示し、2032年には63億米ドルに達すると予測しています。世界の片頭痛治療市場の成長は、片頭痛の同化、治療プロセスに関する知識の拡大、CGRPベースの薬剤のような治療法の開拓、予防治療の促進、新興市場での拡大機会の高まりによって大きく牽引されています。

片頭痛治療市場分析

主要市場促進要因世界の片頭痛の罹患率の増加が、片頭痛治療市場のシェアを大きく伸ばす重要な要因です。片頭痛という病気に対する認識と治療の選択肢の増加が、片頭痛治療の高い需要を後押ししています。さらに、CGRP治療など、より健康的な治療法の開発に注力する主要企業による研究開発活動の活発化が、市場動向に好影響を与えています。

主要市場動向：片頭痛治療市場の動向には、予防薬への注目の高まりと治療経路の改善が含まれます。新製品発売や提携など、市場参入企業の戦略的行動により、このセグメントにおける治療法やイノベーションの数がエスカレートしています。

地理的動向：北米が片頭痛治療市場を支配しているのは、主要参入企業の存在、支援的な償還政策、精密医療への注力のためです。片頭痛の広範な増加と患者の転帰改善への関心の高まりも、同地域の市場拡大に寄与する要因です。

競合情勢：片頭痛治療業界の主要市場参入企業には、Abbott Laboratories、Allergan Plc (Abbvie Inc.),、Amgen Inc.,、AstraZeneca Plc、Bausch Health Companies Inc. (旧Valeant Pharmaceuticals)、Eisai Co. Ltd.、Eli Lilly and Company、Endo International Plc、GlaxoSmithKline Plc、Johnson & Johnson、Merck & Co.、Novartis AG、Pfizer Inc.、Sanofi SA、Teva Pharmaceutical Industries Limitedがあります。

課題と機会：市場は、医薬品の副作用の出現や厳しい規則などの課題に直面しています。さらに、片頭痛の罹患率が高いアジア諸国の拡大や、より効果的な中世の新しい治療法の開発に機会があります。

片頭痛治療市場傾向：

認知と診断の増加

片頭痛の認知度の高まりと、その極めて身体的な障害をもたらすタイプの結果は、片頭痛治療の需要を増大させています。片頭痛の有病率に関しては、訪問者が診断されなかったり、治療が不十分であったりする状況が続いています。例えば、疾病管理予防センター（CDC）を含む政府保健機関の主要役割は、片頭痛について人々に指導することであり、その結果、医療支援を求める病人の数が増加しています。さらに、より多くの人々が効率的な治療の必要性を認識するようになると、治療に対する需要も高まり、市場の成長を後押しします。CDCによると、米国では片頭痛に悩む人は女性の約20％、男性の約9％です。これは人口のかなりの割合です。片頭痛が重大な健康問題であるという認識の高まりは、片頭痛患者と医療専門家の両方が、最も有望な片頭痛治療のバリエーションを探すことを促進しています。

医薬品開発の進歩

科学と医薬品開発の継続的な向上が、片頭痛治療市場の収益を牽引しています。製薬部門では、片頭痛患者のための革新的な治療法の研究開発が重要な仕事の一つです。これには、新しいデリバリーシステムやドラッグ製剤の使用を含め、有効性、安全性、投与方法に優れた薬剤の使用が含まれます。米国国立衛生研究所（NIH）のデータによると、片頭痛治療に関連する臨床試験が現在100以上進行中であり、研究界が治療法を求めて熱い視線を送っているという見方が強まるばかりです。発見されるたびに、患者にとってさまざまな選択肢が利用できるようになり、治療法が改善され、片頭痛患者の生活環境が改善されるという、新たな市場のニッチが開かれるのです。

医療支出の増加

世界中で医療支出が増加しており、片頭痛治療市場の展望は明るいです。政府と民間の方法は、医療システムと社会に差し迫った影響を与えることが知られている片頭痛のような病気の予防と軽減に、ますます多くの資金を集中させています。世界保健機関（WHO）によると、世界の医療支出は、主に慢性疾患管理状態に対処するために、一定の拡大傾向を経験しています。その結果、これらの人々は医療産業のサービスや治療法へのアクセスが容易になり、片頭痛治療の需要が高まっています。このパターンは新興市場で最も顕著であり、片頭痛はより広まりつつあり、その結果、片頭痛の症状を管理するために提供する治療法や介入方法という点で、製薬会社に特定の道を提供することになります。

片頭痛治療市場セグメンテーション：

IMARC Groupは、市場の各セグメントにおける主要動向の分析と、2024～2032年の世界、地域、国レベルの予測を提供しています。当レポートでは、治療タイプ、薬剤タイプ、投与経路、流通チャネルに基づいて市場を分類しています。

治療タイプ別内訳

予防治療が市場シェアの大半を占める

本レポートでは、治療タイプ別に市場を詳細に区分・分析しています。これには、頓挫的治療と予防的治療が含まれます。報告書によると、予防治療が最大のセグメントを占めています。

予防治療は、片頭痛発作の頻度と強度を減少させ、患者の生活の質を向上させることが証明されているため、片頭痛治療市場を支配しています。米国国立衛生研究所（NIH）の報告によると、米国では片頭痛患者の38％が予防的治療を求めているが、その治療を受けているのはごく一部です。前者は、予防法の必要性が首尾一貫して満たされていないことを強調しています。片頭痛は恒常的なものであり、それに対する最良の薬は予防的なものであるという事実に後押しされ、医師や患者の間では、急性症例に予防薬を使用する傾向が強まっています。したがって、このような動向の高まりにより、片頭痛管理の中核として予防的アプローチが必要とされています。

薬剤タイプ別内訳

トリプタン系薬剤が業界最大シェア

本レポートでは、薬剤タイプ別の市場の詳細な区分と分析も行っています。これには、トリプタン、エルゴットアルカロイド、NSAIDs、アセチルコリン阻害剤/神経毒、ダイタン、CGRP mAbs、その他が含まれます。報告書によると、トリプタン系薬剤が最大の市場シェアを占めています。

片頭痛治療市場予測によると、片頭痛治療は、頭痛、頸部痛、吐き気、光や騒音に対する過敏性などの片頭痛症状を迅速に緩和する能力に根ざしているため、トリプタン系薬剤が市場をリードしています。例えば、米国国立神経疾患・脳卒中研究所（NINDS）の報告によると、米国で最も処方率が高いトリプタンは、米国で急性片頭痛治療に医師が最もよく使用する薬剤です。トリプタン系薬剤は、血管内の交感神経線維を興奮させ、脳への痛み信号の伝達を阻害することで効果を発揮します。米国では片頭痛の経験者が女性で20％以上、男性で9％以上いるため、トリプタンのような効果的な急性期治療の入院治療にはまだ決定的な空白があります。トリプタンの人気が高まり、医療プロバイダーの間で広く受け入れられていることは、急性発作治療の片頭痛治療市場におけるトリプタンの位置づけを証明するものであり、患者は痛みを和らげるトリプタンの能力を信頼することができます。

投与経路別内訳

市場セグメンテーションでは経口剤が主要セグメントを占める

本レポートでは、投与経路別に市場を詳細に区分・分析しています。これには経口剤、注射剤、その他が含まれます。同レポートによると、経口剤が最大のセグメントを占めています。

経口投与経路は、患者が医師の監督なしに自宅や外出先で治療を自己管理できる経口薬の利便性と使いやすさから、片頭痛治療市場の値を牽引しています。米国国立神経疾患・脳卒中研究所（NINDS）によると、医療従事者が片頭痛の治療として最も頻繁に使用するのは経口薬です。また、経口剤は他の経路に比べて作用発現が早いため、急性の片頭痛発作にある患者を容易に救済することができます。米国女性の20％、男性の9％に片頭痛が見られることから、経口治療に対する需要が高まっています。これらの治療法の入手しやすさと有効性から、経口薬ルートの優位性が片頭痛治療市場に当てはまる。

流通チャネル別内訳

本レポートでは、流通チャネル別の市場の詳細区分と分析も行っています。これには、病院ベースの薬局、小売薬局、その他が含まれます。

病院を拠点とする薬局は病院内にあり、入院患者や外来患者に医薬品や医薬品サービスを提供しています。片頭痛治療市場において、病院内薬局は救急部や外来クリニックを片頭痛の急性治療患者が利用しやすくするために重要な役割を果たしています。病院内薬局では、片頭痛治療に特化したトリプタン系薬剤やその他の物質を含む、多種多様な薬剤を在庫しています。そのため、急性片頭痛患者への迅速なアクセスと投与が可能です。

小売薬局は、商業地域や住宅街にある薬局で、処方薬や市販薬を一般に販売しています。小売薬局と並んで、急性治療と予防治療の両方を必要とする片頭痛患者は、治療の主要ポイントであるこれらの薬局を利用します。薬局は患者へのカウンセリングやサポートを提供しており、これは医薬品を正しく使用し、治療レジメンを厳格にフォローアップするために重要です。小売薬局は利便性を提供するため、片頭痛に悩む患者をケアすることで、片頭痛治療の流通と入手の主要参入企業として台頭してきています。

地域別内訳

北米が市場をリードし、最大の片頭痛治療市場シェアを占める

本レポートでは、北米（米国、カナダ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、ロシア、その他）、アジア太平洋（中国、日本、インド、韓国、オーストラリア、インドネシア、その他）、ラテンアメリカ（ブラジル、メキシコ、その他）、中東アフリカを含む主要地域市場についても包括的に分析しています。報告書によると、片頭痛治療の最大市場は北米です。

北米が市場を独占しているのは、同地域における疾患の有病率の高さによるものであり、同地域は強固な医療インフラと高い医療支出を誇っており、これが市場成長のバックボーンとなっています。米国国立神経疾患・脳卒中研究所（NINDS）のデータによると、米国人の10人に1人が片頭痛持ちです。それとは別に、北米には抗偏頭痛薬の開発を主要業務とする大手製薬会社が複数あり、研究や製品開発ができる環境が整っています。さらに、米国食品医薬品局（FDA）などの政府機関が、片頭痛治療の迅速な承認に努めていることも、この地域の市場拡大に寄与しています。その結果、これらの力によって北米は世界の片頭痛治療業界のトップレベルを維持しています。

競合情勢：

市場競争情勢も包括的に分析しています。すべての主要企業の詳細プロファイルも提供しています。片頭痛治療業界の主要市場参入企業には、Abbott Laboratories、Allergan Plc (Abbvie Inc.),、Amgen Inc.,、AstraZeneca Plc、Bausch Health Companies Inc. (旧Valeant Pharmaceuticals)、Eisai Co. Ltd.、Eli Lilly and Company、Endo International Plc、GlaxoSmithKline Plc、Johnson & Johnson、Merck & Co.、Novartis AG、Pfizer Inc.、Sanofi SA、Teva Pharmaceutical Industries Limitedがあります。

（これは主要参入企業の一部であり、完全なリストは報告書に記載されていることに留意されたい）。

片頭痛治療市場の主要参入企業は、常に研究開発と商業化の段階に取り組んでおり、片頭痛患者のニーズを満たすことを目指しています。アムジェン、イーライリリー、テバ・ファーマシューティカル・インダストリーズなどの製薬会社は、急性片頭痛の治療と予防のために、カルシトニン遺伝子関連ペプチド（CGRP）阻害薬やゲパントなどの最先端治療を推進しています。例えば、片頭痛治療市場の調査によると、米国国立衛生研究所（NIH）は、各社が現在、薬剤の安全性と有効性を評価することを目的とした試験の参加者を登録中であると報告しています。このようなそれぞれのイニシアチブの発展、片頭痛全般に関する意識の向上、適切な治療へのアクセスもまた、これらの企業の優先事項の一つです。

片頭痛治療市場ニュース

2022年2月、Biohaven PharmaceuticalとPfizerは、片頭痛治療の選択肢におけるリメゲパントの有効性を明らかにすることを目的として、アジア太平洋で実施された第3相臨床試験の良好なトップライン結果を明らかにしました。この試験では、妊娠中の片頭痛とそれに伴う症状に対するリメゲパントの有効性と安全性が実証されました。リメゲパントは、カルシトニン遺伝子関連ペプチド（CGRP）レセプターを標的とする微小分子であり、急性片頭痛発作を速やかに終息させる効果があることが証明されました。このデータは、アジア諸国における片頭痛患者の治療アクセスの進歩における重要な一歩であり、リメゲパントの薬事承認につながる可能性があります。

2022年1月、BioDelivery Sciencesは片頭痛治療の先駆けであるエリキシブ（セレコキシブ内用液）を発表しました。本剤は、前兆の有無にかかわらず、急性片頭痛発作の迅速な治療として食品医薬品局（FDA）により承認された、非常に効果的な成人用内服液剤の一つです。Elyxybの製剤は液状であるため、患者にとって適用が迅速かつ容易であり、片頭痛の症状を止めるための効率的なアプローチを記載しています。この新しい製品の採用は、これまで自由に使える治療法が不十分であった片頭痛患者に対する同社の努力と配慮を反映しています。

本レポートで扱う主要質問

  • 世界の片頭痛治療市場はこれまでどのように推移してきたか？
  • 世界の片頭痛治療市場における促進要因、抑制要因、機会は何か？
  • 各駆動要因、抑制要因、機会が世界の片頭痛治療市場に与える影響は？
  • 主要地域市場とは？
  • 最も魅力的な片頭痛治療市場はどの国か？
  • 治療タイプ別の市場内訳は？
  • 片頭痛治療市場で最も魅力的な治療タイプはどれか？
  • 薬剤タイプ別の市場内訳は？
  • 片頭痛治療市場における最も魅力的な薬剤タイプは？
  • 投与経路別の市場内訳は？
  • 片頭痛治療市場で最も魅力的な投与経路は？
  • 流通チャネル別の市場内訳は？
  • 片頭痛治療市場において最も魅力的な流通チャネルはどこか？
  • 市場の競合構造は？
  • 世界の片頭痛治療市場における主要参入企業/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の片頭痛治療市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：治療タイプ別

  • 頓挫治療
  • 予防治療

第7章 市場内訳：薬剤タイプ別

  • トリプタン
  • 麦角アルカロイド
  • NSAIDs
  • アセチルコリン阻害剤/神経毒
  • ディタンス
  • CGRPモノクローナル抗体
  • その他

第8章 市場内訳：投与経路別

  • 経口
  • 注射
  • その他

第9章 市場内訳：流通チャネル別

  • 病院併設薬局
  • 小売薬局
  • その他

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Allergan Plc（Abbvie Inc.）
    • Amgen Inc.
    • AstraZeneca Plc
    • Bausch Health Companies Inc.（旧Valeant Pharmaceuticals）
    • Eisai Co. Ltd.
    • Eli Lilly and Company
    • Endo International Plc
    • GlaxoSmithKline Plc
    • Johnson & Johnson
    • Merck & Co.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Teva Pharmaceutical Industries Limited
図表

List of Figures

  • Figure 1: Global: Migraine Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Migraine Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Migraine Drugs Market: Breakup by Treatment Type (in %), 2023
  • Figure 4: Global: Migraine Drugs Market: Breakup by Drug Type (in %), 2023
  • Figure 5: Global: Migraine Drugs Market: Breakup by Route of Administration (in %), 2023
  • Figure 6: Global: Migraine Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Migraine Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Migraine Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 9: Global: Migraine Drugs (Abortive Treatment) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Migraine Drugs (Abortive Treatment) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Migraine Drugs (Preventive Treatment) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Migraine Drugs (Preventive Treatment) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Migraine Drugs (Triptans) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Migraine Drugs (Triptans) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Migraine Drugs (Ergot Alkaloids) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Migraine Drugs (Ergot Alkaloids) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Migraine Drugs (NSAIDs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Migraine Drugs (NSAIDs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Migraine Drugs (Acetylcholine Inhibitors/ Neurotoxins) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Migraine Drugs (Acetylcholine Inhibitors/ Neurotoxins) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Migraine Drugs (Ditans) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Migraine Drugs (Ditans) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Migraine Drugs (CGRP mAbs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Migraine Drugs (CGRP mAbs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Migraine Drugs (Other Drug Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Migraine Drugs (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Migraine Drugs (Oral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Migraine Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Migraine Drugs (Injectable) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Migraine Drugs (Injectable) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Migraine Drugs (Other Routes of Administration) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Migraine Drugs (Other Routes of Administration) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Migraine Drugs (Hospital-Based Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Migraine Drugs (Hospital-Based Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Migraine Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Migraine Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Migraine Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Migraine Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: North America: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: North America: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: United States: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: United States: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Canada: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Canada: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Asia Pacific: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Asia Pacific: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: China: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: China: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Japan: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Japan: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: India: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: India: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: South Korea: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: South Korea: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Australia: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Australia: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Indonesia: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Indonesia: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Others: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Others: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Europe: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Europe: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Germany: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Germany: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: France: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: France: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: United Kingdom: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: United Kingdom: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Italy: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Italy: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Spain: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Spain: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Russia: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Russia: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Others: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Others: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Latin America: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Latin America: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Brazil: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Brazil: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Mexico: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Mexico: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Others: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Others: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Middle East and Africa: Migraine Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Middle East and Africa: Migraine Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Global: Migraine Drugs Industry: SWOT Analysis
  • Figure 88: Global: Migraine Drugs Industry: Value Chain Analysis
  • Figure 89: Global: Migraine Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Migraine Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Migraine Drugs Market Forecast: Breakup by Treatment Type (in Million US$), 2024-2032
  • Table 3: Global: Migraine Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 4: Global: Migraine Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 5: Global: Migraine Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 6: Global: Migraine Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Migraine Drugs Market Structure
  • Table 8: Global: Migraine Drugs Market: Key Players
目次
Product Code: SR112024A2543

The global migraine drugs market size reached US$ 4.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.3 Billion by 2032, exhibiting a growth rate (CAGR) of 4.3% during 2024-2032. The global migraine drugs market growth is significantly driven by the increasing assimilation of migraines, expanding knowledge of treatment processes, the development of therapies like CGRP-based drugs, the promotion of preventive treatments, and the rising expansion opportunities in emerging markets.

Migraine Drugs Market Analysis:

Major Market Drivers: The increasing incidence of migraines worldwide is the crucial factor for the significant growth in migraine drugs market share. The rise in recognition of the disease and the option for treatment is fueling the high demand for migraine medicines. Moreover, the rise of research and development activities by the main actors focusing on the development of healthier treatments such as CGRP treatment is having a positive effect on the market trend.

Key Market Trends: The migraine drug market trends include the increasing focus on preventive medications and the improvements in treatment pathways. Strategic actions of market players, for instance, new product launches and partnerships, have escalated the number of therapies and innovations in the field.

Geographical Trends: North America dominates the migraine drugs market due to the presence of key players, supportive reimbursement policies, and a focus on precision medicine in the region. The widespread rise of migraines and the growing focus on improving patient outcomes are other factors that contribute to the expansion of the market in this region.

Competitive Landscape: Some of the major market players in the migraine drugs industry include Abbott Laboratories, Allergan Plc (Abbvie Inc.), Amgen Inc., AstraZeneca Plc, Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals), Eisai Co. Ltd., Eli Lilly and Company, Endo International Plc, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Limited, among many others.

Challenges and Opportunities: The market faces challenges including the emergence of the side effects of medicines and the strict rules and regulations. Moreover, opportunities lie in expanding Asian countries, where the rate of migraine stays high and the development of new, more effective medieval treatments.

Migraine Drugs Market Trends:

Increasing Awareness and Diagnosis

The increase in the perception of migraine headaches and their extremely disabling type of outcome has augmented the migraine drugs demand. As for its prevalence, visitors continue to be undiagnosed or undertreated. The primary role of government health agencies, including, for example, the Centers for Disease Control and Prevention (CDC), is to instruct people about migraines resulting in the increased number of sick individuals who seek medical support. Additionally, as more people become aware of the necessity for efficient treatments, they also contribute to the demand for treatments, which fuels the market growth. According to the CDC, there is approximately 20% of women and 9% of man who are suffering from migraines in the United States. It is a significant percentage of the population. This increasing appreciation of migraines as a significant health matter promotes both migraine patients and healthcare professionals to search for the most prospective migraine treatment variation.

Advancements in Drug Development

Ongoing improvement in scientific and drug development drives the migraine drugs market revenue. In the pharmaceutical sector, the research and development of innovative treatments for migraine sufferers present one of the important workloads. This involves the use of medications that are superior in efficacy, safety, and administration modes, including the use of new delivery systems or drug formulations. According to the National Institutes of Health (NIH) data, over 100 clinical trials associated with migraine treatment are currently ongoing, which only strengthens the view that the research community is hot on the heels in search of the treatment. Every discovery opens a new market niche in which different options are becoming available for patients, and the treatment becomes better, improving the living conditions of migraineurs people.

Rising Healthcare Expenditure

The rising healthcare expenditure around the world is creating a positive migraine drug market outlook. The governments and the private methods are concentrating more and more funds on the prevention and reduction of diseases like migraines which are known to imminently affect healthcare systems and society. As per the World Health Organization (WHO), worldwide healthcare spending has been experiencing a constant trend of expansion, largely to deal with chronic disease management conditions. As a result, these people gain easier access to the healthcare industry services and cures, escalating the demand for migraine medicine. This pattern is the most prominent in the emerging markets, in which migraines are getting more widespread and this in turn provides specific avenues for pharmaceutical companies in terms of the therapies and interventions they provide for managing the symptoms of migraines.

Migraine Drugs Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on treatment type, drug type, route of administration, and distribution channel.

Breakup by Treatment Type:

Abortive Treatment

Preventive Treatment

Preventive treatment accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the treatment type. This includes abortive treatment and preventive treatment. According to the report, preventive treatment represented the largest segment.

Preventive dominates the migraine drugs market as it has proved to help reduce the frequency and intensity of migraine attacks, thereby improving the quality of life of the patients. As per the reports of the National Institutes of Health (NIH), 38% of migraineurs in the United States are looking for preventive treatment, whereas only a marginal section of them receives it. The former emphasizes the coherent unmet necessity for preventive methods. Driven by the fact that migraines are constant and that the best medicine against them is a preventative one, there has been an increasing trend among doctors and patients to use preventive medications for acute cases. So, this growing trend requires preventive approaches as the core of migraine management.

Breakup by Drug Type:

Triptans

Ergot Alkaloids

NSAIDs

Acetylcholine Inhibitors/ Neurotoxins

Ditans

CGRP mAbs

Others

Triptans hold the largest share of the industry

A detailed breakup and analysis of the market based on the drug type have also been provided in the report. This includes triptans, ergot alkaloids, NSAIDs, acetylcholine inhibitors/neurotoxins, ditans, CGRP mAbs, and others. According to the report, triptans accounted for the largest market share.

Based on the migraine drugs market forecast, triptans leads the market as migraine drugs are rooted in their ability to provide speedy relief from migraine symptoms, with special emphasis on headaches, neck pain, nausea as well as sensitivity to light and noise. For instance, as per the reports of the National Institute of Neurological Disorders and Stroke (NINDS) triptans, which has the highest prescription rate in the US, is the class of medication most commonly used by doctors for acute migraine treatment in the United States. They exert their effect by exciting sympathetic fibers in the blood vessels and by obstructing the passage of pain signals to the brain. With more than 20% of women and 9% of men with migraine experience in the U.S., there is still critical inpatient care gaps in effective acute treatments like triptans. Their growing popularity and widespread acceptance among healthcare providers prove their place in the migraine drugs market for acute attacks treatment, allowing patients trust their abilities to relieve pain.

Breakup by Route of Administration:

Oral

Injectable

Others

Oral represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the route of administration. This includes oral, injectable, and others. According to the report, oral represented the largest segment.

Oral route of administration drives the migraine drugs market value due to the convenience and ease of use of oral medications that allow patients to self-administer the treatment at home or on the go without medical supervision. According to the National Institute of Neurological Disorders and Stroke (NINDS), oral medications are the most frequently used treatment for migraine by healthcare providers. Its oral formulation also results in a faster onset of action compared to other routes, which facilitates relief for patients who are amid an acute migraine attack. Due to the existence of migraines among 20% of US women and 9% of men, there has been a rise in demand for oral treatments. The accessibility and effectiveness of these treatments make the dominance of the oral drug route applicable to the migraine drugs market.

Breakup by Distribution Channel:

Hospital-Based Pharmacies

Retail Pharmacies

Others

A detailed breakup and analysis of the market based on the distribution channel have also been provided in the report. This includes hospital-based pharmacies, retail pharmacies, and others.

Hospital-based pharmacies are hospital-based and are situated in hospitals, offering medicinal products and pharmaceutical services to inpatients and outpatients. In the migraine drugs markets, hospital-based pharmacies play a vital role in making emergency departments or outpatient clinics accessible to acute migraine treatment patients. They have an expanded variety of medications in stock, that include triptans and other substances that are specific to the treatment of migraine. This ensures quick access and administration to acute migraine patients.

Retail pharmacies are pharmacies that are located in commercial and residential neighborhoods and offer prescription and over-the-counter drugs to the public. Alongside retail pharmacies, migraine patients who need both acute and preventive treatments turn to these pharmacies to access their drugs as it is a key point of care. They render counseling and support to patients, which is important for the correct usage of medicines and strict follow-up of treatment regimens. As retail pharmacies offer convenience that, they are emerging as key players in the distribution and availability of migraine medications by taking care of the migraine sufferers, even in distinct communities around.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest migraine drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represented the largest market for migraine drugs.

North America dominates the market due to the high prevalence of diseases in the area, whereas the region boasts of a robust healthcare infrastructure and high healthcare spending, which form the backbone for market growth. Based on data from the U.S National Institute of Neurological Disorders and Stroke (NINDS), one out of every 10 Americans have migraines. Apart from that, North America has several big pharmaceutical companies that mainly deal with the development of anti-migraine drugs therefore setting up an environment that allows for research and product development. In addition, efforts by government agencies such as the US Food and Drug Administration (FDA) to ensure the speed of approval of drugs for the treatment of migraines also contribute to the region's market spreading. As a result, these forces keep North America at the top level of the worldwide migraine drugs industry.

Competitive Landscape:

The migraine drugs market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the migraine drugs industry include Abbott Laboratories, Allergan Plc (Abbvie Inc.), Amgen Inc., AstraZeneca Plc, Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals), Eisai Co. Ltd., Eli Lilly and Company, Endo International Plc, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Sanofi SA and Teva Pharmaceutical Industries Limited.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The key players in the migraine drugs market are constantly working on the research and development and commercialization stages and aim at fulfilling the needs of the migraine sufferers. Pharmaceutical concerns such as Amgen, Eli Lilly, and Teva Pharmaceutical Industries are among the industry players that are promoting cutting-edge therapies, for instance, calcitonin gene-related peptide (CGRP) inhibitors and gepants, for both treatment of acute migraines and prophylaxis. For instance, as per the migraine drugs market research U.S. National Institutes of Health (NIH) reports that the companies are currently enrolling participants for trials whose purpose is to evaluate the drugs for their safety and efficacy. The development of these respective initiatives, the rising of awareness about migraines in general, and access to proper treatment are also among the priorities of these companies.

Migraine Drugs Market News:

In February 2022, Biohaven Pharmaceutical and Pfizer revealed positive top-line results with a Phase 3 clinical trial, which was conducted in the Asia-Pacific region and aimed to determine rimegepant's effectiveness in the option of migraine treatment. This study demonstrated effective and safe rimegepant application for pregnant migraine and its associated symptoms. Rimegepant, a tiny molecule targeting calcitonin gene-related peptide (CGRP) receptors, proved to be effective in ending acute migraine attacks speedily. The data ascertains a momentous step in migraine sufferers' therapeutic accessibility progress in the Asian national region, which could potentially lead to regulatory approval of rimegepant.

In January 2022, BioDelivery Sciences introduced Elyxyb (celecoxib oral solution) which is pioneering in the field of migraine treatment. It is among the highly effective adult ready-to-use oral solutions approved by the Food and Drug Administration (FDA) as a quick remedy for acute migraine attacks either with or without aura. Elyxyb's formulation comes in a liquid form, which makes its application fast and easy for the patients, thus providing them with an efficient approach to stop the symptoms of migraines. The introduction of this novel product reflects the company's effort and concern toward migraine patients, who had inadequate treatment methods at their disposal in the past, now this new product offers them the chance to improve their quality of life significantly.

Key Questions Answered in This Report:

  • How has the global migraine drugs market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global migraine drugs market?
  • What is the impact of each driver, restraint, and opportunity on the global migraine drugs market?
  • What are the key regional markets?
  • Which countries represent the most attractive migraine drugs market?
  • What is the breakup of the market based on the treatment type?
  • Which is the most attractive treatment type in the migraine drugs market?
  • What is the breakup of the market based on the drug type?
  • Which is the most attractive drug type in the migraine drugs market?
  • What is the breakup of the market based on the route of administration?
  • Which is the most attractive route of administration in the migraine drugs market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the migraine drugs market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global migraine drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Migraine Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Abortive Treatment
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Preventive Treatment
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Triptans
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Ergot Alkaloids
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 NSAIDs
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Acetylcholine Inhibitors/ Neurotoxins
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Ditans
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 CGRP mAbs
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectable
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital-Based Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Allergan Plc (Abbvie Inc.)
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 SWOT Analysis
    • 15.3.3 Amgen Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 SWOT Analysis
    • 15.3.4 AstraZeneca Plc
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Eisai Co. Ltd.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Eli Lilly and Company
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Endo International Plc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 GlaxoSmithKline Plc
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Johnson & Johnson
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Merck & Co.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Novartis AG
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Pfizer Inc.
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis
    • 15.3.14 Sanofi SA
      • 15.3.14.1 Company Overview
      • 15.3.14.2 Product Portfolio
      • 15.3.14.3 Financials
      • 15.3.14.4 SWOT Analysis
    • 15.3.15 Teva Pharmaceutical Industries Limited
      • 15.3.15.1 Company Overview
      • 15.3.15.2 Product Portfolio
      • 15.3.15.3 Financials
      • 15.3.15.4 SWOT Analysis